[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100304506":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":24,"studyPopulation":13,"armGroups":25,"interventions":38,"overallOfficials":52,"centralContacts":56,"locations":61,"responsibleParty":77,"collaborators":13,"id":80,"slug":13,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":13,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":13,"enrollmentInfo":89,"targetDuration":13,"studyType":92,"phases":93,"briefSummary":96,"conditions":97,"keywords":13,"overallStatus":99,"whyStopped":13,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Zion Therapeutics, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Endophthalmitis after cataract surgery","Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.","Subjects will undergo eye examinations at one day, one week, and one month post-operatively",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":19,"maskingDescription":13,"whoMasked":20},"TRIPLE",[21,22,23],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.",[26,32],{"label":27,"type":28,"description":29,"interventionNames":30},"Treatment group","ACTIVE_COMPARATOR","Intracameral injection of moxifloxacin solution after cataract surgery",[31],"Drug: Moxifloxacin",{"label":33,"type":34,"description":35,"interventionNames":36},"Placebo group","PLACEBO_COMPARATOR","Intracameral injection of placebo after cataract surgery",[37],"Drug: Placebo",[39,46],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Moxifloxacin","Intracameral injection",[27],[45],"active",{"type":40,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Placebo","intracameral injection",[33],[51],"sham",[53],{"name":54,"affiliation":5,"role":55},"Jason Ahee, M.D.","PRINCIPAL_INVESTIGATOR",[57],{"name":54,"role":58,"phone":59,"phoneExt":13,"email":60},"CONTACT","435-862-9865","aheejason@hotmail.com",[62],{"facility":63,"status":13,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Zion Eye Institute","St. George","Utah","84790","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-113.58412,37.10415,{"lat":73,"lon":72},[76],{"name":54,"role":58,"phone":13,"phoneExt":13,"email":13},{"type":78,"investigatorFullName":54,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Medical Director","100304506",false,"NCT03244072","Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery","Inclusion Criteria:\n\n* visually significant cataracts\n\nExclusion Criteria:\n\n* allergy to fluoroquinolones, cobalamin (B12)",true,"ALL","40 Years",{"count":90,"type":91},60000,"ESTIMATED","INTERVENTIONAL",[94,95],"PHASE2","PHASE3","Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis",[98],"Endophthalmitis","NOT_YET_RECRUITING","2025-09-21",{"date":102,"type":103},"2025-09-25","ACTUAL",{"date":105,"type":91},"2026-06-01",{"date":107,"type":91},"2031-10",{"name":54,"class":6},1]